Prospective studies on autologous and allogeneic transplantation as part of first-line therapy in T-cell lymphoma
| Reference . | n . | Histology . | PFS/EFS . | OS . | n (%) of patients transplanted . | Cause of failure to proceed to transplantation (n) . |
|---|---|---|---|---|---|---|
| 39 | 160 | NOS, 62; AITL, 30; ALCL, ALK−, 3; EATL, 21; other, 16 | 44% at 5 y | 51% at 5 y | 115 (72) to autologous HSCT | PD (26), toxic death (7), protocol violation (2), mobilization fail (2), other (4) |
| 40 | 83 | NOS, 32; AITL, 27; ALCL, ALK−, 13; other, 11 | 36% at 3 y | 48% at 3 y | 55 (66) to autologous HSCT | PD (24), toxic death (2), patient decision (2) |
| 41 | 62 | NOS, 28; AITL, 10; ALCL, ALK+, 19; other, 5 | 30% at 12 y | 34% at 12 y | 46 (74) to autologous HSCT | PD (11), mobilization fail (2), patient decision (2) |
| 42 | 41 | NOS, 20; AITL, 12; other, 9 | 30% at 4 y | 39% at 4 y | 17 (41) to autologous SCT | PD (16), relapse (1), toxic death (1), mobilization fail (3), poor performance (2), patient decision (1) |
| 43 | 61 | NOS, 33; AITL, 14; ALCL, ALK−, 12; EATL, 2 | 26% at 4 y | 31% at 4 y | 38 (62) to allogeneic or autologous HSCT | PD (18), toxic death (5) |
| 44 | 58 | NOS, 25; AITL, 16; ALCL, ALK−, 7; other, 8 | 41% at 1 y | 69% at 1 y | 36 (62) to allogeneic or autologous HSCT | PD (17), toxic death (1), change of histology (2), no donor (5) |
| Reference . | n . | Histology . | PFS/EFS . | OS . | n (%) of patients transplanted . | Cause of failure to proceed to transplantation (n) . |
|---|---|---|---|---|---|---|
| 39 | 160 | NOS, 62; AITL, 30; ALCL, ALK−, 3; EATL, 21; other, 16 | 44% at 5 y | 51% at 5 y | 115 (72) to autologous HSCT | PD (26), toxic death (7), protocol violation (2), mobilization fail (2), other (4) |
| 40 | 83 | NOS, 32; AITL, 27; ALCL, ALK−, 13; other, 11 | 36% at 3 y | 48% at 3 y | 55 (66) to autologous HSCT | PD (24), toxic death (2), patient decision (2) |
| 41 | 62 | NOS, 28; AITL, 10; ALCL, ALK+, 19; other, 5 | 30% at 12 y | 34% at 12 y | 46 (74) to autologous HSCT | PD (11), mobilization fail (2), patient decision (2) |
| 42 | 41 | NOS, 20; AITL, 12; other, 9 | 30% at 4 y | 39% at 4 y | 17 (41) to autologous SCT | PD (16), relapse (1), toxic death (1), mobilization fail (3), poor performance (2), patient decision (1) |
| 43 | 61 | NOS, 33; AITL, 14; ALCL, ALK−, 12; EATL, 2 | 26% at 4 y | 31% at 4 y | 38 (62) to allogeneic or autologous HSCT | PD (18), toxic death (5) |
| 44 | 58 | NOS, 25; AITL, 16; ALCL, ALK−, 7; other, 8 | 41% at 1 y | 69% at 1 y | 36 (62) to allogeneic or autologous HSCT | PD (17), toxic death (1), change of histology (2), no donor (5) |
PD, progressive disease.